Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase II study of HS-20137 injection in adults with moderate to severe plaque psoriasis
CTR20252679Phase 2Active
- Sponsor
- Qiansin
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of QX004N in plaque psoriasis, sponsored by Qiansin. Started Jul 2025; status: active.
02
Drugs
QX004N
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on CTR20252679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252679.